 - The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction ENACT-AMI trial is a Canadian, 5-center, phase IIb, double-blind, parallel, randomized placebo controlled trial assessing the safety and efficacy of cell and gene therapy for patients with moderate to large anterior STEMI and who have undergone re-vascularization with stent implantation to the infarct related artery IRA. The anticipated recruitment target is 100 patients over a two-year period. 